Mondias receives positive results from greenhouse production tests conducted on CELEXT07 with leading cannabis producer
Momentum Public Relations
Press Release: March 18, 2019
Canada NewsWire
MONTREAL, March 18, 2019
- Foliar application of CELEXT07 bio-defense stimulant extract alone or in combination with a botanically-derived antimicrobial plant extract results in the prevention and suppression of powdery mildew on cannabis leaves.
- CELEXT07 is a strong alternative to synthetic fungicides for cannabis growers in search of eco-friendly alternatives.
- CELEXT07 extract is ready to market: production capacity secured to meet demand from potential clients.
MONTREAL, March 18, 2019 /CNW/ – Mondias Naturals Inc. (“Mondias” or the “Company”) (TSXV: NHP) is pleased to announce the results of its greenhouse production tests conducted in collaboration with McGill University and a leading cannabis producer on its proprietary CELEXT07 bio-defense stimulant plant extract.
Mondias has been developing CELEXT07 to help prevent fungal growth on plants through its proven ability to boost plant defense systems. The objective of the tests was to measure the product’s efficacy in reducing and suppressing the most common fungal diseases encountered in cannabis through the application of CELEXT07 alone and in combination with a botanically-derived antimicrobial plant extract grown in greenhouse production systems.
Summary of the test results:
- Preliminary results showed that foliar application of CELEXT07 alone resulted in the prevention of powdery mildew on cannabis leaves.
- Foliar application of CELEXT07 combined with the tested botanically-derived antimicrobial plant extract resulted in the prevention and suppression of powdery mildew on the leaves of three commercial varieties of cannabis. This combination was the most effective in protecting the cannabis variety most susceptible to powdery mildew.
- When applied alone or in combination with the tested botanically-derived antimicrobial plant extract as a foliar spray, CELEXT07 did not produce any phytotoxic effects on cannabis leaves.
- Soil drench application of CELEXT07 helped suppress grey mould on hops, a close relative of cannabis.
“These results validate the effectiveness of CELEXT07’s bio-defense stimulant properties and open up a large potential market for Mondias, especially as the testing was done in collaboration with a leading cannabis producer,” said Jean-Philippe Gravel, Chief Executive Officer of Mondias. “Furthermore, cannabis growers are seeking eco-friendly alternatives to pesticides. The results from these greenhouse production tests will allow us to market CELEXT07 to a growing number of Canadian cannabis producers. The product is ready to market, and we have secured the production capacity we need to meet demand from potential clients.”
With post-harvest losses of one-third of the food produced worldwide for human consumption (Gastavsson et al., 2011) and annual economic losses of $10 billion to $100 billion worldwide due to grey mould and powdery mildew (L. Hua et al., 2018), the market potential for CELEXT07 is considerable.
About Mondias Natural Products Inc.
Mondias specializes in the commercialization and development of evidence-based botanical products for the health care, bio-agriculture and organic markets. The company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. Mondias is also developing botanical-based specialty fertilizers for use on household plants, lawns and golf courses and in urban gardens, nurseries and greenhouses, in collaboration with McGill’s Faculty of Agricultural and Environmental Sciences.
For more information, visit: mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of this joint venture, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
SOURCE Mondias Natural Products Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2019/18/c6020.html
Contact:
Mondias Natural Products Inc., Jean-Philippe Gravel, Chief Executive Officer, 514-804-4569, jpgravel@mondias.ca
- Published in Cannabis, Life Sciences, Marijuana, Mondias Natural, News Home
Grown Rogue Bringing Proven Growth Model to Large Michigan Cannabis Market for 2019
Momentum Public Relations
Press Release: March 12, 2019
Grown Rogue International Inc. (CSE:GRIN | OTC: NVSIF) (“Grown Rogue” or the “Company”), a vertically-integrated, multi-state cannabis company, with licenses and operations in Oregon and California, is bringing its winning brand and business model which generated compound monthly sales growth of 14% during the 2018 calendar year in Oregon – one of the world’s most competitive cannabis markets – into the newly legalized recreational cannabis market in Michigan. Grown Rogue anticipates gaining meaningful traction for its brand through its local partnership with licensed operators in the State of Michigan.
Oregon is among the most competitive cannabis markets in the United States based on total active cultivation and licenses per capita. According to an August 2018 report from Oregon-Idaho High Intensity Drug Trafficking Area (HIDTA), “Oregon has more than a thousand licensed recreational marijuana growers, with roughly 900 more in the queue to receive licenses. There’s one licensed cultivation operation for every 19 consumers.” Despite this competition, Grown Rogue launched its first cannabis products in late 2017 into the Oregon market and gained sales traction and market share as a result of high-quality products, unique branding and effective marketing. By the end of 2018 Grown Rogue branded products were available in more than half of Oregon dispensaries.
A number of factors contributed to Grown Rogue’s overall success in 2018:
- Optimization of cultivation and distribution teams;
- Major increase in outdoor harvest from 2017 to 2018 by over 50% based on training and efficiency programs implemented in early 2018;
- Accolades in product quality in Oregon by setting outdoor potency record and winning the prestigious Growers Cup in 2 of 3 categories;
- Established partnership with international award winning chocolatier;
- Expansion into California with a 16,000 sq ft micro business facility with retail, processing, and distribution licensing.
“Launching Grown Rogue in Oregon required fastidious planning and execution in order to be successful,” said Obie Strickler, Founder and CEO. “We properly navigated the regulatory environment for recreational cannabis and refined the preferred consumer experience around brands and product selection, and established innovations in product development and packaging. Operating in a State like Oregon that was early to legalize cannabis has provided a tremendous amount of intellectual, operational, and cultivation expertise. We also have significant understanding of the cannabis consumer and evolving cannabis products and formats. We are taking this expertise and applying it into new states and are particularly optimistic about the tremendous opportunity in Michigan.”
Michigan is the first state in the Midwest to vote for the legalization of recreational cannabis . Michiganhas the largest medical cannabis population per capita and is second only to California in total medical users. As a relative comparison, the state of Michigan has a population of approximately 10 million people and about 313,000 registered medical cannabis patients according to Michigan Live, or 3.1%, compared to Canada with a population of approximately 38 million, which had 342,103 registered medical patients at September 30, 2018 according the Health Canada, or 0.9% where cannabis is fully legal at both provincial and federal levels.
By any measure, Michigan has one of the most active medical cannabis markets in America which is a leading indicator in the potential size of the recreational market.
Number of legal medical marijuana patients in the U.S. as of May 2018, by state according to ProCon.org:
STATE |
# OF MEDICAL MARIJUANA PATIENTS |
STATE POPULATION |
# OF PATIENTS PER 1,000 RESIDENTS |
Michigan |
269,553 |
9,9962,311 |
27.06 |
California |
915,845 |
39,536,653 |
23.16 |
Colorado |
88,946 |
5,607,154 |
15.86 |
Oregon |
45,210 |
4,142,776 |
10.91 |
Washington |
80,818 |
7,405,743 |
10.91 |
Massachusetts |
48,265 |
6,859,819 |
7.04 |
Grown Rogue’s current expected portfolio in Michigan includes two strategically positioned retail centers (known as provisional licenses) in Hazel Park and Midtown Detroit as well as a 19,000 sq ft cultivation center in Detroit. Additional license acquisitions are being reviewed.
“Our expansion into Michigan has the potential to add substantial value to the overall business. Our track record of growth to date should give current and future shareholders the confidence that we will continue to perform in the exciting Michigan market,” added Jacques Habra, Chief Strategy Officer.
Grown Rogue expects Michigan operations to begin generating revenue in late 2019.
About Grown Rogue
Grown Rogue International (CSE: GRIN | OTC: NVSIF) is a vertically-integrated, multi-state cannabis company curating innovative products to provide consumers with the right cannabis experience. Each of Grown Rogue’s products and strains are categorized and marketed based on unique effects and designed for the full range of a consumers’ lifestyle. Grown Rogue is scaling the vertically integrated model into multiple states by incorporating best-in-class manufacturing facilities and a proprietary distribution platform based on Microsoft technology. Grown Rogue’s diverse cannabis product suite includes premium flower, patent-pending nitrogen sealed pre-rolls, oil and concentrates, and edibles featuring a partnership with world-renowned chocolatier, Jeff Shepherd.
Diagnos to redeem 10% debentures, roll back shares 1:10
Momentum Public Relations
Press Release: March 11, 2019
Diagnos Inc. has taken steps to reorganize its debt and capital structure to allow it to efficiently allocate its resources and pursue the growth of the business. As such, Diagnos has put in place a special reorganization team to cover all strategic, legal, organizational and financial aspects of the proposed reorganization.
For the purpose of reorganizing the debt
Diagnos will be holding a meeting for the holders of the 10 per cent secured convertible debentures on April 4, 2019, to obtain their approval for a proposed amendment to the debentures which would allow the corporation to immediately redeem the principal amount in the aggregate amount of $4.94-million, plus accrued interest, on the debentures payable in common shares of the corporation at the deemed issue price of 3.5 cents per share (being 35 cents postconsolidation (as defined herein)). If the debenture redemption is not approved, the corporation will seek approval to amend the terms of the debentures to allow the corporation to: (i) make the interest payments in the form of shares; and (ii) repay the debentures at maturity, in the form of shares, based on a share price equal to the volume-weighted average price (VWAP) of the corporation’s shares for the five days prior to the interest payment date or the maturity date.
If the debenture redemption is approved, the corporation will seek to convert the 10 per cent unsecured convertible notes outstanding in the aggregate principal of $1-million, at the redemption price, by private contract.
The debenture redemption, the debenture amendments and the note redemption are subject to the approval of the TSX Venture Exchange and compliance with the TSX-V corporate finance manual (policies), which establishes a minimum share issuance price of five cents. Accordingly, approval of the consolidation is required before the transactions contemplated herein can take place.
For the purpose of reorganizing its capital structure
The corporation will be holding a special meeting of its shareholders on April 10, 2019, to obtain approval for an amendment to the corporation’s articles to allow it to proceed with a share consolidation on the basis of one postconsolidated share being outstanding for every 10 preconsolidation shares. If passed, the consolidation will take place as soon as possible and the corporation will proceed shortly thereafter with the debenture redemption, if passed and, the note redemption, as may be applicable.
Benefits and management recommendation
The board of directors, acting in good faith and with a view of the corporation’s best interest, believes the proposed reorganization to be fair to all of its stakeholders as it will allow Diagnos to move forward with the development of the business. The board recommends that the debentureholders vote in favour of the debenture redemption and that the shareholders vote in favour of the consolidation, for the following reasons:
- Reduced risk: The corporation has missed interest payments on the debentures. It does not have, nor does it anticipate having, the financial capacity to redeem the Series 1 debentures due July 29, 2019, in cash, or that it could do so without severely impacting its commercialization efforts. The debenture redemption would significantly reduce the risks of default by the corporation, ensure its continuity and provide debentureholders with a redemption price that is aligned with the market value of the shares, all the while preserving the opportunity to generate capital appreciation and participate in the growth of the corporation’s business.
- Facilitate capital raises; favourable capital structure: The corporation will require additional working capital to move forward with the growth of the business. By removing $6.6-million of debt from its balance sheet (and, in so doing, eliminating the threat to the corporation’s continuity and use of its assets) and by presenting an attractive capital structure (40.2 million shares outstanding at a higher share price), the corporation expects this will facilitate the injection of new capital and generate interest on a broader level from a variety of investors, including institutional investors.
- Removes important barriers to business development: Adding new users is key to building a strong client base for the corporation’s AI (artificial intelligence) tools in the medical field. It is a lengthy process requiring sustained efforts and support, namely during the trial process, and uncertainties as to the long-term viability of the corporation is an important barrier to business development. By presenting a stronger financial position, potential customers and business partners, both in the private and public sectors, will be less hesitant to invest resources, time and money, in the product adoption process.
- Favourable redemption price: The proposed redemption price is highly favourable as conversion prices are currently at 10 cents for the Series 1 and Series 3 debentures, 15 cents for the Series 2 debentures, and 16 cents for the notes, and, following the consolidation, the conversion prices would be adjusted to, respectively, $1, $1.50 and $1.60. Moreover, the TSX-V policies do not permit reductions in the conversion price of convertible securities to a price that would be below the common share price at the time of issuance of the convertible security, other than in the context of a debt reorganization.
Pro forma share structure following the reorganization
The corporation currently has 212,931,265 shares outstanding, debentures in the aggregate principal amount of $4.94-million and notes in the aggregate principal amount of $1-million. The attached table presents the pro forma share structure of the corporation assuming the debenture redemption, the note redemption and the consolidation are approved.
Debt Maturity Outstanding Shares issued Shares aggregate based on outstanding principal redemption price postconsolidation Series 1 -- Senior 10% secured convertible debentures July 29, 2019 $1,530,000 43,714,285 4,371,428 Series 2 -- 10% secured convertible debentures April 13, 2020 $2,610,000 74,571,428 7,457,142 Series 3 -- 10% secured convertible debentures July 4, 2021 $800,000 22,857,142 2,285,714 Total for the secured debentures $4,940,000 141,142,855 14,114,284 10% convertible notes Oct. 13, 2020 $900,000 25,714,285 2,571,428 10% convertible notes Oct. 23, 2020 $100,000 2,857,142 285,714 Total for the convertible notes $1,000,000 28,571,427 2,857,142 Accrued interest (to April 17, 2019) $687,822 19,652,045 1,965,204 Conversion; consolidation $(6,627,822) 189,366,327 18,936,630 Outstanding debt; shares 0 402,297,592 40,229,759
Corporate update
Commercialization efforts have increased in the recent year and management expects sales will steadily improve as it is building a customer base by creating awareness for its Flaire platform with continuing trials, which are generating excellent results. Although the slow rates of adoption for innovative products in the medical industry have been and continue to be an important challenge for the corporation, moving forward, Diagnos is gaining an in-depth understanding of the process and the company expects to build, from these early adopters, a strong client base. In addition to CARA (computer-assisted retina analysis) being commercialized, Diagnos has been actively developing other health-care-focused software tools as well, which are in different phases of development. Cardio is another important software being tested by Diagnos in four countries, which has strong growth potential. A few other health-care-focused software tools, which are presently in the development phase, include hypertensive retinopathy, OCT (optical coherence tomography), sleep apnea and Alzheimer’s disease.
Recent key highlights:
- Sept. 18, 2018 — Diagnos reaches agreement with 20/20NOW, the leading ocular telehealth provider in the United States;
- Nov. 13, 2018 — Addition of strategic partner in Mexico;
- Nov. 11, 2018 — Diagnos closed a private placement of approximately $1-million and attracted a new strategic investor;
- Dec. 4, 2018 — Diagnos signs a collaborative agreement with a renowned engineering school in Montreal for the accelerated development of new innovative features for CARA based on deep learning applications;
- Jan. 22, 2019 — Diagnos announces extension to the diabetic retinopathy screening services assisted by artificial intelligence (AI) at the Centre Hospitalier de l’Universite de Montreal (CHUM) following the excellent initial results from trial;
- Jan. 29, 2019 — Diagnos strengthens the board with the addition of Dr. Jean-Francois Yale, an endocrinologist and professor of medicine at McGill with specific interest in the prevention and management of diabetes.
Meeting of debentureholders April 4, 2019
The meeting of the debentureholders will take place on April 4, 2019, at 10:30 a.m., at the offices of the corporation, located at 7005 Taschereau Blvd., Suite 340, Brossard, Que. Debentureholders will be asked to approve the debenture redemption and alternatively approve the debenture amendements. Debentureholders are urged to carefully review the management information circular they will receive as well as the voting instructions provided. For the debenture redemption or the debenture amendments resolutions to be passed, a quorum representing 25 per cent or more of the outstanding principal amount of the debentures must be represented, in person or by proxy, at the meeting, of which debentureholders having no less than 66-2/3rds per cent of the principal value of the debentures must vote in favour. The debenture redemption remains subject to approval by the TSX-V, and any and all further shares issuances will also be subject to the approval of the TSX-V, at the time of issuance. If a share issuance would result in the creation of a new insider or dominant shareholder (meaning, respectively, having control over 10 per cent and 20 per cent of more of the corporation’s securities), the approval of the TSX-V and/or of the shareholders may be required. However, at this time, the corporation does not anticipate the creation of new insiders or control persons pursuant to the reorganization.
All securities issued and issuable to the debentureholders and/or noteholders will be subject to a four-month-and-one-day hold period from the date of issuance, and it is a condition that all shares issuances contemplated herein be made in compliance with exemptions of prospectus and/or registration requirements under applicable securities laws.
Meeting of shareholders April 10, 2019
The shareholder meeting will take place on April 10, 2019, at 10 a.m., at the offices of the corporation, located at 7005 Taschereau Blvd., Suite 340, Brossard, Que. The shareholders will be asked to approve an amendment to its articles of incorporation to proceed with the 1:10 consolidation of its shares, following which every 10 preconsolidation shares held will be converted to one postconsolidation share. All convertible securities issued and outstanding will be adjusted in the same ratio, in quantity and in price, on the effective date. Shareholders of record on March 12, 2019, will receive a proxy solicitation and management information circular, which will include the details of the consolidation and voting instructions. The resolution approving the consolidation must be approved by no less than 66-2/3rds per cent of the shareholders, in person or represented by proxy, at the meeting.
About Diagnos Inc.
Diagnos is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its artificial intelligence tool CARA. CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA is accessible securely over the Internet; is compatible with all recognized image formats and brands of fundus cameras; and is EMR (electronic medical record) compatible. CARA complies with local regulations; is FDA (U.S. Food and Drug Administration) cleared for commercialization in the United States; is Health Canada licensed for commercialization in Canada; and is CE marking compliant in Europe.
- Published in Diagnos
Crystal Lake Maiden Drilling at Burgundy Ridge Confirms Copper-Rich New Discovery
Momentum Public Relations
Press Release: March 8, 2019
Crystal Lake Mining Corporation (TSXV: CLM, the “Company” or “CrystalLake“), is pleased to announce that results from first-ever drilling last fall at Burgundy Ridge confirm a new grassroots discovery in the footprint of approximately two dozen showings and mineral zones at the Company’s 430 sq. km Newmont Lake Project northwest of Eskay Creek.
Widespread surface mineralization at Burgundy Ridge extends to depth, including 2.6% copper between 118 meters and 119.5 meters in the fourth and final shallow hole, in a multi-element copper-rich porphyry-skarn system.
Burgundy Ridge is now believed to be part of a >3 km-long northeast trending mineral corridor situated west of a series of under-explored high-grade gold occurrences and targets, along with the historic Northwest gold zone. Importantly, all of these mineral zones and associated host rocks are within a graben structure bounded by the 20-km-long McLymont Fault. This makes the Newmont Lake Project a highly favorable geological environment for new discoveries.
Reverse circulation (RC) first-pass drilling of four shallow holes totaling 550 meters was completed from one set-up at the top of Burgundy Ridge as restrictive winter conditions set in at an elevation of approximately 1,900 meters.
Highlights:
- Final hole of program (BRRC18-004) cut 58 meters @ 0.31% Cu and 0.27 g/t Au starting from surface, followed by a 1.5-meter interval grading 2.60% Cu from 118m to 119.5m;
- Each hole intersected copper-rich mineralization, with gold and silver, associated with intense and widespread “skarn style” alteration of the multi-phase intrusions and immediate host rocks;
- Evidence suggests that mineralization strengthens with depth;
- Drilling confirmed a previously unmapped and well-endowed intermediate intrusive rock consisting of pervasive chalcopyrite blebs and fine-grained disseminated bornite mineralization.
Richard Savage, President and CEO, commented: “The cover has been lifted off Burgundy Ridge with geologists fascinated by their first look at what’s below surface at a dynamic target that not long ago was completely hidden by snow and ice.
“To have hit on each hole in maiden drilling during extremely challenging conditions last fall, confirming a new early stage discovery high in the system in this prolific district, gives us a huge edge entering our 2019 diamond drilling program and sets the table for a potential major new find,” Savage concluded.
High-Energy Mineralized System
Impressive surface alteration and mineralization at Burgundy Ridge, exposed by a rapidly receding glacier, has been mapped over several hundred meters and is now known to extend to depth following first-ever drilling. This new discovery is on trend with the ’72 Zone, Telena and Andrei targets which show similar characteristics as Burgundy Ridge based on mapping, surface sampling and geophysics. All areas will be explored aggressively in 2019.
Multiple surface targets exist at Burgundy Ridge including a lower elevation higher-grade zone, identified through sampling, providing ample additional discovery opportunities in 2019 as glacial retreat accelerates and diamond drilling tests this mineralized system over a broader area and at much greater depths.
Tight correlations between copper and silver, copper and gold, and copper and cobalt are indicative of a coherent style of mineralization created through a systematic process, elevating the potential of the Burgundy Ridge system. Meanwhile, the copper-gold rich skarn at the interface between mineralized intrusions and carbonate rocks at Burgundy Ridge reflects a higher fluid-rock ratio typical of proximal skarn along a porphyry system. Zoned calc-silicate skarns are commonly formed from fluids associated with very large porphyry systems.
Significant assay results – Burgundy Ridge RC holes 1 through 4*
Hole |
From |
To |
Interval |
Cu |
Au |
Ag |
Co |
Zn |
(m) |
(m) |
(%) |
(g/t) |
(%) |
(%) |
(%) |
||
BRRC18-004 |
0.0 |
58.5 |
58.5 |
0.31 |
0.27 |
1.41 |
– |
– |
and |
118.0 |
119.5 |
1.5 |
2.60 |
0.03 |
16.70 |
0.011 |
0.44 |
BRRC18-003 |
22.0 |
47.9 |
25.9 |
0.4 |
0.10 |
2.25 |
– |
– |
including |
41.8 |
43.3 |
1.5 |
1.41 |
0.20 |
7.50 |
0.021 |
0.04 |
and |
66.0 |
69.0 |
3.0 |
0.65 |
0.47 |
11.76 |
– |
0.96 |
including |
66.0 |
67.5 |
1.5 |
1.05 |
0.84 |
18.80 |
0.014 |
1.19 |
BRRC18-002 |
1.5 |
17.4 |
16.1 |
0.34 |
0.17 |
2.54 |
– |
– |
BRRC18-001 |
5.2 |
15.9 |
10.7 |
0.41 |
0.32 |
2.70 |
– |
– |
and |
49.4 |
55.5 |
6.1 |
0.68 |
0.22 |
3.97 |
– |
1.55 |
including |
49.4 |
52.4 |
3.0 |
1.16 |
0.23 |
9.50 |
0.020 |
2.85 |
*True widths cannot be determined with the information and data currently available |
Drill hole co-ordinates
Drill Hole |
Easting (mE) |
Northing (mN) |
Elevation (m) |
Depth (m) |
Azimuth (°) |
Dip (°) |
BRRC18-01 |
374976 |
6303130 |
1828 |
150 |
135 |
-60 |
BRRC18-02 |
374976 |
6303130 |
1828 |
100 |
315 |
-60 |
BRRC18-03 |
374976 |
6303130 |
1828 |
150 |
315 |
-75 |
BRRC18-04 |
374976 |
6303130 |
1828 |
150 |
135 |
-75 |
Newmont Lake Project
Crystal Lake has an option to earn a 100% interest in the Newmont Lake Project from Romios Gold Resources (TSXV: RG) – refer to February 25, 2019, news release.
QA/QC Statement on Assay Results
Crystal Lake employed rigorous Quality Assurance and Quality Control (QAQC) protocols in line with best industry standards and practices for geochemical analysis. In the field, three rotating standards and a blank were inserted every 25th sample. Three types of standards were purchased from Ore Research & Exploration Laboratories Pty Ltd (ORE). A common granite-gravel aggregate was used as a blank. Additionally, MS Analytical used in-house blanks, and added two sets of duplicates to further improve the QAQC methodology. Two aggregate blanks were analyzed before each hole to ensure proper cleaning between sample batches. Up to six duplicates per hole were used to test FAS-211, ICP-240 and IMS-230 assay results. Both reject and pulp duplicate tests were performed.
Samples were prepared at MS Analytical in Terrace, BC, using PPU-510 (Pulverize 250g to 85% passing 75-micron) due to the lack of crushing required for RC chips. The sample pulps were then transported to MS Analytical Laboratory in Langley, BC, for geochemical analysis. A FAS-211 analysis (Gold by Fire Assay and AAS finish) was used with detection up to 100 ppm with an over limit analysis FAS-415 (Detection up to 1000 ppm). Gold is reported in parts per million (ppm) equivalent to grams per tonne (g/t). ICP-240 analysis was used as a 33-element ore-grade geochemistry method, therefore no over limit analysis was necessary (four-acid digestion with ICPES finish). These analytical results are reported in percentage apart from silver (Ag), which is reported as parts per million (ppm). Silver analysis was retested using IMS-230 to provide a lower detection limit of 0.01 ppm to ensure accurate findings.
Qualified Person
The technical information in this news release has been reviewed and approved by Mr. Adbul Razique, PhD., P.Geo., a Qualified Person responsible for the scientific and technical information in this news release under National Instrument 43-101 standards.
About Crystal Lake Mining
Crystal Lake Mining is a Canadian-based junior exploration company focused on building shareholder value through high-grade discovery opportunities in British Columbia and Ontario. The Company has an option to earn a 100% interest in the Newmont Lake Project, one of the largest land packages among juniors in the broader Eskay region in the heart of Northwest B.C.’s Golden Triangle.
On behalf of The Board of Directors of Crystal Lake Mining Corporation
Richard Savage, President & CEO
This news release may contain certain “forward looking statements”. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Any forward-looking statement speaks only as of the date of this news release and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Crystal Lake Mining Corporation
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2019/07/c3943.html
Contact:
MarketSmart Communications Inc., Tel: +1 (604) 261-4466, Toll free: 1-877- 261-4466, Email: info@marketsmart.ca; Momentum PR, Tel: +1 (514) 815-7473, Email: mark@momentumpr.com
- Published in Crystal Lake Mining, Mining, News Home
Crop’s Elite Partners With MYM Nutraceuticals on 120 Acres of Nevada Hemp
Momentum Public Relations
Press Release: March 7, 2019
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today it has entered into an agreement with MYM Nutraceuticals Inc., (CSE: MYM) (OTCBB: MYMMF) (“MYM”) to partner with CROP’s subsidiary, Elite Ventures Group LLC., on 120 acres of CBD-rich hemp in Nevada, USA.
Under the agreement, MYM will fund Elite with $500,000 USD in exchange for the rights to 50% of CBD rich hemp grown on a 120 acre parcel of land in Nevada. In consideration for the investment, Elite will provide all the necessary capital and consumable supplies, plant, grow and harvest the hemp. If requested, Elite will also arrange for the processing and sale of the biomass at no less favourable terms that those found in the Elite supply agreements.
Based on Elite’s previous success in cultivating 120 acres of similarly situated land in August 2018, the estimated production of hemp from the MYM parcel of land is 120,000 pounds per harvest with a CBD level of 10%-19%. This represents potential revenue of over $26 million, of which MYM is entitled to 50% less processing and sales fees.
CROP CEO, Michael Yorke, stated: “This is very significant partnership arrangement with Vancouver-based MYM Nutraceuticals which has operations in three countries and will bring additional exposure to our organic hemp products.”
About CROP
Crop is publicly listed company trading under symbol CROP.CSE. The company is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of Hemp CBD farms, and a growing portfolio of common share equity in upcoming listings within the cannabis space. CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line and 16 Cannabis brands.
About MYM
MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and hemp. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Cannabis, CROP Infrastructure, hemp, Marijuana, News Home